Aerovate Therapeutics (NASDAQ:AVTE) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Aerovate Therapeutics (NASDAQ:AVTE) issued its quarterly earnings data on Tuesday. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.03, Zacks reports.

Aerovate Therapeutics Trading Down 0.4 %

Shares of AVTE traded down $0.01 on Thursday, reaching $2.62. 74,888 shares of the company’s stock traded hands, compared to its average volume of 616,882. The stock’s 50 day simple moving average is $2.18 and its two-hundred day simple moving average is $6.33. The stock has a market cap of $75.64 million, a PE ratio of -0.88 and a beta of 1.00. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $32.42.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.